Oglufanide

About the Target

Oglufanide (H-Glu-Trp-OH, L-Glutamyl-L-tryptophan), a dipeptide immunomodulator isolated from calf thymus, inhibits vascular endothelial growth factor (VEGF), also stimulates the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. The mapped biological anchor for this entry is Vascular endothelial growth factor A (VEGFA), although the description suggests that interpretation should remain at fragment, family, or pathway level. This biological context is frequently studied in relation to cytokine balance, leukocyte function, and host-defense signaling, where small changes in pathway tone can propagate into broader inflammatory phenotypes. In infection-oriented models, investigators often connect this biology with host-pathogen signaling, antiviral responses, and inflammatory control. This framing is especially useful when investigators want to connect controlled pathway perturbation with broader changes in inflammatory state.

Research Context

Because the description includes both inhibition and immunomodulation, the cleanest interpretation usually comes from combining target-proximal biomarkers with broader inflammatory readouts. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because the enrichment is not fully single-target, conclusions are usually strongest when they are framed around the intended biological process and confirmed with orthogonal markers.

• monitor cytokine, chemokine, or immune-cell state readouts alongside phenotypic endpoints
• compare effects across basal and stimulated inflammatory conditions when possible
• separate direct immunomodulatory activity from secondary tissue or pathway responses

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

For routine mechanistic work, the unmodified catalog format provides a consistent starting point for concentration-response studies, benchmark experiments, and orthogonal validation. In comparative workflows, consistency of preparation, exposure window, and matched controls is often as important as the nominal treatment itself. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.